D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2016 Feb 27

PMID 26915421

Citations 14

Authors

Donald C Goff

Affiliations

Soon will be listed here.

Abstract

Background: Dysregulation of N-methyl D-aspartate (NMDA) receptor signaling is strongly implicated in schizophrenia. Based on the ketamine model of NMDA receptor hypoactivity, therapeutic approaches designed to maintain a sustained increase in agonist activity at the glycine site of the NMDA receptor have produced promising, although inconsistent, efficacy for negative symptoms.

Methods: A review of the published literature on D-cycloserine (DCS) pharmacology in animal models and in clinical studies was performed. Findings relevant to DCS effects on memory and plasticity and their potential clinical application to schizophrenia were summarized.

Results: Studies in animals and clinical trials in patients with anxiety disorders have demonstrated that single or intermittent dosing with DCS enhances memory consolidation. Preliminary trials in patients with schizophrenia suggest that intermittent dosing with DCS may produce persistent improvement of negative symptoms and enhance learning when combined with cognitive behavioral therapy for delusions or with cognitive remediation. The pharmacology of DCS is complex, since it acts as a "super agonist" at NMDA receptors containing GluN2C subunits and, under certain conditions, it may act as an antagonist at NMDA receptors containing GluN2B subunits.

Conclusions: There are preliminary findings that support a role for D-cycloserine in schizophrenia as a strategy to enhance neuroplasticity and memory. However, additional studies with DCS are needed to confirm these findings. In addition, clinical trials with positive and negative allosteric modulators with greater specificity for NMDA receptor subtypes are needed to identify the optimal strategy for enhancing neuroplasticity in schizophrenia.

Citing Articles

Importance of Modulating Kynurenic Acid Metabolism-Approaches for the Treatment of Dementia.

Baran H, Jan Pietryja M, Kepplinger B Biomolecules. 2025; 15(1).

PMID: 39858468 PMC: 11764436. DOI: 10.3390/biom15010074.

Design of ()-3-(5-Thienyl)carboxamido-2-aminopropanoic Acid Derivatives as Novel NMDA Receptor Glycine Site Agonists: Variation in Molecular Geometry to Improve Potency and Augment GluN2 Subunit-Specific Activity.

Zhao F, Atxabal U, Mariottini S, Yi F, Lotti J, Layeux M J Med Chem. 2025; 68(3):3572-3590.

PMID: 39847708 PMC: 11832032. DOI: 10.1021/acs.jmedchem.4c02715.

Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.

Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X Int J Mol Sci. 2024; 25(19).

PMID: 39408997 PMC: 11477438. DOI: 10.3390/ijms251910668.

Noninvasive Brain Stimulation for Neurorehabilitation in Post-Stroke Patients.

Li K, Wu J, Zhou Z, Xu D, Zheng M, Hua X Brain Sci. 2023; 13(3).

PMID: 36979261 PMC: 10046557. DOI: 10.3390/brainsci13030451.

Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments.

Martinez A, Brea J, Rico S, Teresa de Los Frailes M, Loza M Int J Mol Sci. 2021; 22(18).

PMID: 34576069 PMC: 8468549. DOI: 10.3390/ijms22189905.

References

Kalisch R, Holt B, Petrovic P, de Martino B, Kloppel S, Buchel C . The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans. Cereb Cortex. 2008; 19(1):187-96. PMC: 2638747. DOI: 10.1093/cercor/bhn076. View

Lisman J, Pi H, Zhang Y, Otmakhova N . A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia. Biol Psychiatry. 2010; 68(1):17-24. PMC: 3507433. DOI: 10.1016/j.biopsych.2010.04.007. View

DSouza D, Radhakrishnan R, Perry E, Bhakta S, Singh N, Yadav R . Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology. 2012; 38(3):492-503. PMC: 3547200. DOI: 10.1038/npp.2012.208. View

Weiser M, Heresco-Levy U, Davidson M, Javitt D, Werbeloff N, Gershon A . A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012; 73(6):e728-34. DOI: 10.4088/JCP.11m07031. View

Goff D . Bitopertin: the good news and bad news. JAMA Psychiatry. 2014; 71(6):621-2. DOI: 10.1001/jamapsychiatry.2014.257. View

Goff D, Keefe R, Citrome L, Davy K, Krystal J, Large C . Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007; 27(6):582-9. DOI: 10.1097/jcp.0b013e31815abf34. View

Peters J, de Vries T . D-cycloserine administered directly to infralimbic medial prefrontal cortex enhances extinction memory in sucrose-seeking animals. Neuroscience. 2012; 230:24-30. DOI: 10.1016/j.neuroscience.2012.11.004. View

Quartermain D, Mower J, Rafferty M, HERTING R, Lanthorn T . Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994; 257(1-2):7-12. DOI: 10.1016/0014-2999(94)90687-4. View

Holt D, Lebron-Milad K, Milad M, Rauch S, Pitman R, Orr S . Extinction memory is impaired in schizophrenia. Biol Psychiatry. 2008; 65(6):455-63. PMC: 3740529. DOI: 10.1016/j.biopsych.2008.09.017. View

10.

Ripke S, ODushlaine C, Chambert K, Moran J, Kahler A, Akterin S . Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013; 45(10):1150-9. PMC: 3827979. DOI: 10.1038/ng.2742. View

11.

van Berckel B, Hijman R, van der Linden J, Westenberg H, van Ree J, Kahn R . Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996; 40(12):1298-300. DOI: 10.1016/S0006-3223(96)00311-3. View

12.

Schwarcz R . The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol. 2004; 4(1):12-7. DOI: 10.1016/j.coph.2003.10.006. View

13.

Burgdorf J, Zhang X, Nicholson K, Balster R, Leander J, Stanton P . GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2013; 38(5):729-42. PMC: 3671991. DOI: 10.1038/npp.2012.246. View

14.

Preskorn S, Baker B, Kolluri S, Menniti F, Krams M, Landen J . An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008; 28(6):631-7. DOI: 10.1097/JCP.0b013e31818a6cea. View

15.

Tuominen H, Tiihonen J, Wahlbeck K . Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2004; 72(2-3):225-34. DOI: 10.1016/j.schres.2004.05.005. View

16.

Sanz-Clemente A, Nicoll R, Roche K . Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist. 2012; 19(1):62-75. PMC: 3567917. DOI: 10.1177/1073858411435129. View

17.

Smits J, Rosenfield D, Otto M, Marques L, Davis M, Meuret A . D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res. 2013; 47(10):1455-61. PMC: 3747985. DOI: 10.1016/j.jpsychires.2013.06.020. View

18.

Vengeliene V, Kiefer F, Spanagel R . D-cycloserine facilitates extinction of conditioned alcohol-seeking behaviour in rats. Alcohol Alcohol. 2008; 43(6):626-9. DOI: 10.1093/alcalc/agn067. View

19.

Floresco S, Zhang Y, Enomoto T . Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behav Brain Res. 2008; 204(2):396-409. DOI: 10.1016/j.bbr.2008.12.001. View

20.

Duffy S, Labrie V, Roder J . D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology. 2007; 33(5):1004-18. DOI: 10.1038/sj.npp.1301486. View